A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

ID Number 15-2243

Principal Investigator(s)
Joshua Brody

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study, which involves research, is to determine if an experimental drug: ACP-196 is safe and effective in the treatment of this disease.

ACP-196 is an investigational drug.  An experimental drug is not approved by the United States Food and Drug Administration (FDA) for use except in research studies.  ACP-196 has been tested previously in approximately 242 humans and has been well tolerated.  ACP-196 is administered as an oral capsule.

Contact Information
Deborah Lehrer

Recruiting Patients: Yes